Kenvue Q1 2025 Earnings: Sales Decline Amid Strategic Shifts, Full-Year Outlook Reaffirmed

Kenvue Inc. (NYSE: KVUE) reported a 3.9% year-over-year decline in net sales for Q1 2025, totaling $3.74 billion, with a 1.2% drop in organic sales and a 2.7% hit from foreign exchange. Gross profit margin improved to 58.0% from 57.6%, though adjusted gross margin dipped slightly to 60.0%. Operating income margin rose to 14.9%, while adjusted operating margin fell to 19.8% from 22.0% due to increased brand investment and volume pressures.

Adjusted EPS came in at $0.24, down from $0.28 a year earlier, while reported EPS was $0.17 versus $0.15. The company cited higher tariffs and FX headwinds for revising its 2025 outlook, now expecting 1–3% net sales growth, organic growth of 2–4%, and flat adjusted EPS year-over-year.

Kenvue completed its Transition Services Agreement (TSA) exits in April, marking a key milestone in its separation from Johnson & Johnson. It also announced a CFO transition effective May 12, 2025.

Kenvue Inc. (NYSE: KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025.

Kenvue declares quarterly dividend

Kenvue Inc. (NYSE: KVUE) announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on common stock. The dividend will be payable on May 28, 2025, to shareholders of record as of May 14, 2025.

Kenvue is the world’s largest pure-play consumer health company by revenue, with a portfolio that includes Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol.

KENVUE OPENS NEW GLOBAL HEADQUARTERS IN SUMMIT, NEW JERSEY

Kenvue Inc. officially opened its new 290,000-square-foot global headquarters in Summit, New Jersey, with a ribbon-cutting ceremony attended by Governor Phil Murphy and other local officials. The move from its previous headquarters in Skillman brings together teams from across seven locations into a collaborative, innovation-focused environment.

The LEED Gold-certified campus includes advanced facilities such as the Insights Lab, Sensory Lab, Design Lab, and a Virtual Experience Room. These spaces are designed to accelerate product development and improve consumer engagement with brands like Neutrogena, Listerine, Aveeno, and Tylenol.

CEO Thibaut Mongon emphasized the company’s commitment to innovation, sustainability, and community partnerships. Local organizations such as Bridges Outreach and GRACE were also recognized during the event. The new headquarters places Kenvue near key talent and further establishes New Jersey as a hub for consumer health innovation.

Kenvue Inc. (NYSE: KVUE) announced its full-year and fourth-quarter 2024 financial results, reporting a mixed performance amid headwinds in the sales growth.

**Fourth Quarter 2024 Financial Results:**
- Net sales decreased by 0.1% to $3.7 billion, with organic sales growing by 1.7%.
- Diluted earnings per share (EPS) were $0.15, while adjusted diluted EPS was $0.26.
- Gross profit margin improved by 80 basis points to 56.5%.
- Operating income margin rose to 13.2%, while adjusted operating income margin decreased to 19.2%.
- Interest expense was $95 million, nearly identical to the previous year.
- The effective tax rate was 15.3%, up from 8.4% in the previous year.

**Full-Year 2024 Financial Results:**
- Net sales increased by 0.1% to $15.5 billion, with organic sales growth of 1.5%.
- Gross profit margin improved by 200 basis points to 58.0%.
- Operating income margin decreased to 11.9%, and adjusted operating income margin was 21.5%.
- Diluted EPS was $0.54, while adjusted diluted EPS was $1.14.
- Interest expense increased to $378 million from $250 million the previous year.
- The effective tax rate increased to 27.2%, and the adjusted effective tax rate was 25.5%.

**2025 Outlook:**
Kenvue expects:
- Net sales change between -1% and +1% year-over-year, with organic sales growth between 2% and 4%.
- A 3% headwind from foreign currency translation.
- Adjusted operating income margin improvement year-over-year.
- Adjusted diluted EPS growth between flat and +2%, with a mid-single-digit unfavorable impact from foreign currency.

Despite the challenges faced in 2024, Kenvue remains optimistic, planning to increase brand investments and focus on productivity gains to fuel future growth. The company noted that it is not able to provide full reconciliation of adjusted measures to GAAP on a forward-looking basis due to the unpredictability of certain factors.